2nd Oral Oncolytics Conference

Oct

28


In order to maximize your product’s potential, join us at CBI’s 2nd Annual Oral Oncolytics Summit and hear from key stakeholders on critical issues surrounding patient initiation, access, reimbursement and adherence.
Philadelphia, PA  |  Hyatt Regency at Penn's Landing

Loreen Brown, SVP of Product Management and Not-for-Profit Operations, Lash Group, and Ana Stojanovska, Sr. Director, Xcenda, co-present "Drive Access and Adherence through Best-­in-­Class Patient and Provider Support Programs."

Key factors to ensuring product access include provider knowledge and the patient’s ability and willingness to adhere to a therapy. This session will explore market access challenges – both current and future - facing oral oncolytics and provide insight on how manufacturers are developing effective support services to address these issues. Topics include:

  • Overview of payer and provider challenges for oral oncology products
  • Impact of ACA and Health Insurance Exchanges on the oncology landscape
  • Considerations for co-pay support programs to improve access
  • Development of customer-centric, integrated learning and support experiences to enhance patient adherence

Studies have shown that oral oncolytics hold some of the highest potential for ROI, currently making up to 35% of the current oncology pipeline.* Yet the patient abandonment rates for these products are incredibly high, due to out-of-pocket cost share and patient non-adherence. In order to maximize your product’s potential, join us at CBI’s 2nd Annual Oral Oncolytics Summit and hear from key stakeholders on critical issues surrounding patient initiation, access, reimbursement and adherence.